SlideShare a Scribd company logo
Presented by
Karan kashyap
M. Pharm (Pharmaceutic’s)
Introduction
• The Medicines and Healthcare products Regulatory Agency
(MHRA) is a government body which of the Department of
Health of United Kingdom was set up in 2003 to bring together
the functions of the Medicines Control Agency (MCA) and the
Medical Devices Agency (MDA).
History
• In 1999, the Medicines Control Agency (MCA) took over
control of the General Practice Research Database (GPRD)
from Office for National Statistics.
• Medicines Control Agency (MCA) and the Medical Devices
Agency (MDA) merged in 2003 to form MHRA.
MCA MDA
+ MHRA
• In April 2012, the GPRD was expanded and re-launched as
the Clinical Practice Research Data-link (CPRD).
• In April 2013, MHRA merged with the National Institute for
Biological Standards and Control (NIBSC) and was rebranded,
with MHRA identity being used for the parent organization
and one of the centres within the group. At the same time
CPRD was formally declared a separate centre of MHRA, too
Function of MHRA
• Clinical trials Preformulation and laboratory tests Drug
discovery Mechanism of action The MHRA has no interest in
these early stages of drug development.
• MHRA comes in play when the company wants to start
clinical trials in patients. Function of MHRA
• It was located in Vauxhall, London and is now relocated to New London.
• Regulation of clinical trials.
• Safety and efficacy monitoring .
• Providing information to public and health professionals .
• Licensing Manufacturer and dealer licenses .
• Clinical trial licenses,.
• Parallel import licenses .& Enforcement of law.
Drug Development Process
Process of Licensing
The MHRA lisceses /authorizes
• Pharmaceutical manufacturers .
• Medicine importers.
• New biological or chemical compounds.
• Different brands of existing medicines.
• Generics (identical but cheaper versions of existing branded
medicines).
• New forms of existing medicines, such as syrups, patches, or
injections.
• prescription only to over the counter use, such as the
cholesterol lowering medicine Simvastatin (Zocor Heart-Pro).
• Traditional herbal medicines sold over the counter that meet
required safety and quality standards .
• Designated authorities (Notified Bodies) that approve the quality
marking system (CE marking) for medical devices /equipment.
• Clinical trials of both medicines and devices, from toothpaste to
gene therapy
• Blood banks that meet required safety and quality standards .
• Applications on humanitarian grounds to use certain medical
devices in the UK not carrying a CE marking.
Renewal of license
• New Marketing authorizations (MAs) are valid for five years
and then may be renewed on the basis of a re-evaluation of
the risk- benefit balance.
• Once renewed, the marketing authorization will be valid for
an unlimited period.
• Applications for renewal should be submitted at least six
months before expiry
Cancellation of liscence
• If MAs holder does not file an application for renewal within
specified time, MAs expires automatically.
• If the MAs holder does not wish to renew the license, a letter
should be sent indicating the cancellation to
 Administrative Support Team
 Medicines and Healthcare products Regulatory Agency
(MHRA).
• MHRA has authority of cancel license of product if it affects
public health.
Export drugs and medicine
• Permission must need to export certain drugs and
medicines.
These are:
 Controlled drugs.
 Drugs that can be used for lethal injections.
 Medicines.
 Export certificates for medicines for animals.
THANK YOU

More Related Content

Similar to Medicine’s & Healthcare Product Regulatory Agency by drkarank

Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agencies
Urmila Aswar
 
Application for New Drug Discovery (NDD) according to USFDA guidelines
Application for New Drug Discovery (NDD) according to USFDA guidelines Application for New Drug Discovery (NDD) according to USFDA guidelines
Application for New Drug Discovery (NDD) according to USFDA guidelines
Bharathiar university
 
Marketing Authorization procedures in developed and developing countries
Marketing Authorization procedures in developed and developing countriesMarketing Authorization procedures in developed and developing countries
Marketing Authorization procedures in developed and developing countriesAkshay Saxena
 
Medicines and Healthcare products Regulatory Agency(MHRA)
Medicines and Healthcare products Regulatory Agency(MHRA)Medicines and Healthcare products Regulatory Agency(MHRA)
Medicines and Healthcare products Regulatory Agency(MHRA)
Rishabh Agrawal
 
Cdsco
CdscoCdsco
121725101005-S1.pptx
121725101005-S1.pptx121725101005-S1.pptx
121725101005-S1.pptx
TridevSastri1
 
Hospital Formulary.ppt
Hospital Formulary.pptHospital Formulary.ppt
Hospital Formulary.ppt
Ravinandan A P
 
Expert review of medicines and medical devices regulation: Prescription medic...
Expert review of medicines and medical devices regulation: Prescription medic...Expert review of medicines and medical devices regulation: Prescription medic...
Expert review of medicines and medical devices regulation: Prescription medic...
TGA Australia
 
Drug Approval Bodies in Canada 101: The Elevator Length Pitch
Drug Approval Bodies in Canada 101: The Elevator Length PitchDrug Approval Bodies in Canada 101: The Elevator Length Pitch
Drug Approval Bodies in Canada 101: The Elevator Length Pitch
Canadian Cancer Survivor Network
 
Pharmacy and therapeutic committee by BNP.pdf
Pharmacy and therapeutic committee by BNP.pdfPharmacy and therapeutic committee by BNP.pdf
Pharmacy and therapeutic committee by BNP.pdf
College of pharmaceutical sciences
 
P. MERIKUMARI
P. MERIKUMARIP. MERIKUMARI
P. MERIKUMARI
Ramesh Ganpisetti
 
Rx15 pharma tues_330_burns
Rx15 pharma tues_330_burnsRx15 pharma tues_330_burns
Rx15 pharma tues_330_burns
OPUNITE
 
IND, NDA, ANDA, SNDA
IND, NDA, ANDA, SNDAIND, NDA, ANDA, SNDA
IND, NDA, ANDA, SNDA
MANIKANDAN V
 
Presentation: Prescription Medicines Reforms
Presentation: Prescription Medicines ReformsPresentation: Prescription Medicines Reforms
Presentation: Prescription Medicines Reforms
TGA Australia
 
ANDA -Abbreviated NewDrug Application.pptx
ANDA -Abbreviated NewDrug Application.pptxANDA -Abbreviated NewDrug Application.pptx
ANDA -Abbreviated NewDrug Application.pptx
BHAGYASHRI BHANAGE
 
Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?
RIAPA
 
Principles of Drug Discovery and Development
Principles of Drug Discovery and DevelopmentPrinciples of Drug Discovery and Development
Principles of Drug Discovery and Development
MANIKANDAN V
 
radc.pptx
radc.pptxradc.pptx
radc.pptx
KajalBhulaiwale
 
Presentation: Medicinal Cannabis - what's happening?
Presentation: Medicinal Cannabis - what's happening?Presentation: Medicinal Cannabis - what's happening?
Presentation: Medicinal Cannabis - what's happening?
TGA Australia
 
Veena Sanjay Katoriya
Veena Sanjay KatoriyaVeena Sanjay Katoriya
Veena Sanjay Katoriya
VEENA18
 

Similar to Medicine’s & Healthcare Product Regulatory Agency by drkarank (20)

Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agencies
 
Application for New Drug Discovery (NDD) according to USFDA guidelines
Application for New Drug Discovery (NDD) according to USFDA guidelines Application for New Drug Discovery (NDD) according to USFDA guidelines
Application for New Drug Discovery (NDD) according to USFDA guidelines
 
Marketing Authorization procedures in developed and developing countries
Marketing Authorization procedures in developed and developing countriesMarketing Authorization procedures in developed and developing countries
Marketing Authorization procedures in developed and developing countries
 
Medicines and Healthcare products Regulatory Agency(MHRA)
Medicines and Healthcare products Regulatory Agency(MHRA)Medicines and Healthcare products Regulatory Agency(MHRA)
Medicines and Healthcare products Regulatory Agency(MHRA)
 
Cdsco
CdscoCdsco
Cdsco
 
121725101005-S1.pptx
121725101005-S1.pptx121725101005-S1.pptx
121725101005-S1.pptx
 
Hospital Formulary.ppt
Hospital Formulary.pptHospital Formulary.ppt
Hospital Formulary.ppt
 
Expert review of medicines and medical devices regulation: Prescription medic...
Expert review of medicines and medical devices regulation: Prescription medic...Expert review of medicines and medical devices regulation: Prescription medic...
Expert review of medicines and medical devices regulation: Prescription medic...
 
Drug Approval Bodies in Canada 101: The Elevator Length Pitch
Drug Approval Bodies in Canada 101: The Elevator Length PitchDrug Approval Bodies in Canada 101: The Elevator Length Pitch
Drug Approval Bodies in Canada 101: The Elevator Length Pitch
 
Pharmacy and therapeutic committee by BNP.pdf
Pharmacy and therapeutic committee by BNP.pdfPharmacy and therapeutic committee by BNP.pdf
Pharmacy and therapeutic committee by BNP.pdf
 
P. MERIKUMARI
P. MERIKUMARIP. MERIKUMARI
P. MERIKUMARI
 
Rx15 pharma tues_330_burns
Rx15 pharma tues_330_burnsRx15 pharma tues_330_burns
Rx15 pharma tues_330_burns
 
IND, NDA, ANDA, SNDA
IND, NDA, ANDA, SNDAIND, NDA, ANDA, SNDA
IND, NDA, ANDA, SNDA
 
Presentation: Prescription Medicines Reforms
Presentation: Prescription Medicines ReformsPresentation: Prescription Medicines Reforms
Presentation: Prescription Medicines Reforms
 
ANDA -Abbreviated NewDrug Application.pptx
ANDA -Abbreviated NewDrug Application.pptxANDA -Abbreviated NewDrug Application.pptx
ANDA -Abbreviated NewDrug Application.pptx
 
Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?
 
Principles of Drug Discovery and Development
Principles of Drug Discovery and DevelopmentPrinciples of Drug Discovery and Development
Principles of Drug Discovery and Development
 
radc.pptx
radc.pptxradc.pptx
radc.pptx
 
Presentation: Medicinal Cannabis - what's happening?
Presentation: Medicinal Cannabis - what's happening?Presentation: Medicinal Cannabis - what's happening?
Presentation: Medicinal Cannabis - what's happening?
 
Veena Sanjay Katoriya
Veena Sanjay KatoriyaVeena Sanjay Katoriya
Veena Sanjay Katoriya
 

Recently uploaded

Digital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion DesignsDigital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion Designs
chanes7
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 
Group Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana BuscigliopptxGroup Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana Buscigliopptx
ArianaBusciglio
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Atul Kumar Singh
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
MysoreMuleSoftMeetup
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
Nguyen Thanh Tu Collection
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
TechSoup
 
Marketing internship report file for MBA
Marketing internship report file for MBAMarketing internship report file for MBA
Marketing internship report file for MBA
gb193092
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
DhatriParmar
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
Celine George
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
EduSkills OECD
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
 
Chapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdfChapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdf
Kartik Tiwari
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
Jisc
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
JosvitaDsouza2
 

Recently uploaded (20)

Digital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion DesignsDigital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion Designs
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 
Group Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana BuscigliopptxGroup Presentation 2 Economics.Ariana Buscigliopptx
Group Presentation 2 Economics.Ariana Buscigliopptx
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
 
Marketing internship report file for MBA
Marketing internship report file for MBAMarketing internship report file for MBA
Marketing internship report file for MBA
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
 
Chapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdfChapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdf
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
 

Medicine’s & Healthcare Product Regulatory Agency by drkarank

  • 1. Presented by Karan kashyap M. Pharm (Pharmaceutic’s)
  • 2. Introduction • The Medicines and Healthcare products Regulatory Agency (MHRA) is a government body which of the Department of Health of United Kingdom was set up in 2003 to bring together the functions of the Medicines Control Agency (MCA) and the Medical Devices Agency (MDA). History • In 1999, the Medicines Control Agency (MCA) took over control of the General Practice Research Database (GPRD) from Office for National Statistics. • Medicines Control Agency (MCA) and the Medical Devices Agency (MDA) merged in 2003 to form MHRA. MCA MDA + MHRA
  • 3. • In April 2012, the GPRD was expanded and re-launched as the Clinical Practice Research Data-link (CPRD). • In April 2013, MHRA merged with the National Institute for Biological Standards and Control (NIBSC) and was rebranded, with MHRA identity being used for the parent organization and one of the centres within the group. At the same time CPRD was formally declared a separate centre of MHRA, too Function of MHRA • Clinical trials Preformulation and laboratory tests Drug discovery Mechanism of action The MHRA has no interest in these early stages of drug development. • MHRA comes in play when the company wants to start clinical trials in patients. Function of MHRA • It was located in Vauxhall, London and is now relocated to New London.
  • 4. • Regulation of clinical trials. • Safety and efficacy monitoring . • Providing information to public and health professionals . • Licensing Manufacturer and dealer licenses . • Clinical trial licenses,. • Parallel import licenses .& Enforcement of law.
  • 7. The MHRA lisceses /authorizes • Pharmaceutical manufacturers . • Medicine importers. • New biological or chemical compounds. • Different brands of existing medicines. • Generics (identical but cheaper versions of existing branded medicines). • New forms of existing medicines, such as syrups, patches, or injections.
  • 8. • prescription only to over the counter use, such as the cholesterol lowering medicine Simvastatin (Zocor Heart-Pro). • Traditional herbal medicines sold over the counter that meet required safety and quality standards . • Designated authorities (Notified Bodies) that approve the quality marking system (CE marking) for medical devices /equipment. • Clinical trials of both medicines and devices, from toothpaste to gene therapy • Blood banks that meet required safety and quality standards . • Applications on humanitarian grounds to use certain medical devices in the UK not carrying a CE marking. Renewal of license • New Marketing authorizations (MAs) are valid for five years and then may be renewed on the basis of a re-evaluation of the risk- benefit balance. • Once renewed, the marketing authorization will be valid for an unlimited period. • Applications for renewal should be submitted at least six months before expiry
  • 9. Cancellation of liscence • If MAs holder does not file an application for renewal within specified time, MAs expires automatically. • If the MAs holder does not wish to renew the license, a letter should be sent indicating the cancellation to  Administrative Support Team  Medicines and Healthcare products Regulatory Agency (MHRA). • MHRA has authority of cancel license of product if it affects public health. Export drugs and medicine • Permission must need to export certain drugs and medicines. These are:  Controlled drugs.  Drugs that can be used for lethal injections.  Medicines.  Export certificates for medicines for animals.